Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
건강한 성인의 SARS-COV-2 변이체 mRNA 백신 부스터의 안전성 및 면역 원성 : 중간 분석
Clinical Trial
[키워드] (Beta)
addition
assessment
assessments
B.1.351
B.1.617.2
Beta
boost
booster
booster dose
booster doses
clinical
COVID-19 vaccine
COVID-19 vaccine mRNA-1273
Delta
dose
evaluate
Exploratory analyses
Exploratory analysis
exploratory interim analysis
Gamma
group
healthy
immunogenicity
include
interim analysis
mRNA
mRNA vaccine
mRNA-1273
mRNA-1273 booster
mRNA-1273.211
multivalent mRNA-1273.211
neutralization
neutralization titer
neutralization titers
Neutralizing antibodies
neutralizing antibody
Open-label
open-label phase 2a study
P.1
RNA vaccines
Safe
Safety
SARS-CoV-2 variant
SARS-CoV-2 variants
significant increase
single booster dose
statistically
susceptibility
titers
Trial
trial participant
undetectable
Vaccine
variant
variant-modified booster
variant-modified boosters
variant-modified mRNAs
variant-specific vaccines
variants
variants of interest
VoC
VOCs
VOIs
waned
wild-type D614G
wild-type D614G virus
[DOI] 10.1038/s41591-021-01527-y PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1038/s41591-021-01527-y PMC 바로가기 [Article Type] Clinical Trial